Ajay K Nooka

List of Publications by Year
in descending order

226 papers	7,998 citations	117625 34 h-index	54911 84 g-index
227 all docs	227 docs citations	227 times ranked	8088 citing authors

#	Article	IF	Citations
1	Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. Transplantation and Cellular Therapy, 2022, 28, 75.e1-75.e7.	1.2	5
2	Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e526-e531.	0.4	10
3	Impact of concurrent gabapentin or pregabalin with highâ€dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Pharmacotherapy, 2022, 42, 233-240.	2.6	1
4	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. Journal of Clinical Oncology, 2022, 40, 3057-3064.	1.6	31
5	Carfilzomib 56â€‰mg/m² twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison. Leukemia and Lymphoma, 2022, 63, 1887-1896.	1.3	3
6	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2022, 40, 3020-3031.	1.6	26
7	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer Journal, 2022, 12, 63.	6.2	5
8	Î² adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma. Haematologica, 2022, 107, 2226-2231.	3.5	3
9	Moving Toward a Cure for Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 1-12.	3.8	2
10	Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2022, 387, 495-505.	27.0	291
11	Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.. Journal of Clinical Oncology, 2022, 40, 8013-8013.	1.6	20
12	Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.. Journal of Clinical Oncology, 2022, 40, 8018-8018.	1.6	8
13	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Journal of Clinical Oncology, 2022, 40, 3808-3816.	1.6	19
14	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. American Journal of Hematology, 2021, 96, E68-E71.	4.1	7
15	Healthâ€related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. British Journal of Haematology, 2021, 193, 561-569.	2.5	10
16	Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare. Blood Cancer Discovery, 2021, 2, 119-124.	5.0	27
17	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. Clinical Cancer Research, 2021, 27, 3178-3189.	7.0	15
18	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood, 2021, 137, 3604-3615.	1.4	44

#	Article	IF	Citations
19	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. EJHaem, 2021, 2, 375-384.	1.0	2
20	Maintenance Strategies for Myeloma. Cancer Journal (Sudbury, Mass), 2021, 27, 231-238.	2.0	0
21	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. British Journal of Haematology, 2021, 194, 784-788.	2.5	7
22	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer Journal, 2021, 11, 103.	6.2	32
23	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncology, 2021, 17, 1987-2003.	2.4	23
24	KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer Journal, 2021, 11, 116.	6.2	44
25	Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Review of Hematology, 2021, 14, 697-706.	2.2	6
26	Longer term outcomes with singleâ€agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13â€month followâ€up from the pivotal DREAMMâ€2 study. Cancer, 2021, 127, 4198-4212.	4.1	89
27	â€œI took the road less traveled, and that has made all the differenceâ€: Making a case for highâ€dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma. Cancer, 2021, 127, 4133-4136.	4.1	2
28	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood Cancer Journal, 2021, 11, 149.	6.2	5
29	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood Cancer Discovery, 2021, 2, 600-615.	5.0	15
30	A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. American Journal of Cancer Research, 2021, 11, 3285-3293.	1.4	0
31	P-170: Transplant related morbidities with Melphalan as conditioning regimen for myeloma autotransplants. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S129.	0.4	1
32	Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients. Blood, 2021, 138, 1616-1616.	1.4	0
33	Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT) Tj ETQq1 1 0.784314 rgBT /Ov	1.4	
34	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. Blood, 2021, 138, 896-896.	1.4	29
35	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. Blood, 2021, 138, 1624-1624.	1.4	0
36	Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The Piper Study. Blood, 2021, 138, 1077-1077.	1.4	0

#	Article	IF	Citations
37	Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma. Blood, 2021, 138, 1611-1611.	1.4	0
38	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.4	0
39	DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021, 138, 897-897.	1.4	7
40	P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for â‰¥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S149-S150.	0.4	2
41	P-208: Ongoing trials investigating in-class transition (iCT) from parenteral to oral proteasome inhibitor (PI)-based treatment with ixazomib in multiple myeloma (MM). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S153.	0.4	0
42	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica, 2020, 105, 468-477.	3.5	41
43	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncology, The, 2020, 21, 207-221.	10.7	544
44	Primary refractory multiple myeloma: a real-world experience with 85 cases. Leukemia and Lymphoma, 2020, 61, 2868-2875.	1.3	6
45	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
46	Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibodyâ€“Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and Therapy, 2020, 9, 889-911.	2.3	101
47	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 797-803.	0.4	5
48	Downregulation of PA28Î± induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood Cancer Journal, 2020, 10, 125.	6.2	7
49	MM-219: Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors and Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S301-S302.	0.4	1
50	MM-350: Daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S308-S309.	0.4	3
51	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. JCO Oncology Practice, 2020, 16, e1169-e1180.	2.9	8
52	Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nature Communications, 2020, 11, 1228.	12.8	62
53	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia, 2020, 34, 2430-2440.	7.2	54
54	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer Journal, 2020, 10, 40.	6.2	15

#	Article	IF	Citations
55	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2020, 38, 1928-1937.	1.6	148
56	Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight, 2020, 5, .	5.0	43
57	DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 19-20.	1.4	27
58	Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 26-27.	1.4	6
59	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Advances, 2020, 4, 181-190.	5.2	16
60	DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2020, 38, 8502-8502.	1.6	32
61	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.. Journal of Clinical Oncology, 2020, 38, 8519-8519.	1.6	13
62	Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).. Journal of Clinical Oncology, 2020, 38, 8536-8536.	1.6	24
63	Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison. Blood, 2020, 136, 8-9.	1.4	1
64	Role of clonoSEQÂ®, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma. Blood, 2020, 136, 50-51.	1.4	0
65	A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis ofClostridium difficileâ€“associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 2019, 68, 196-203.	5.8	41
66	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	27.0	460
67	Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer Journal, 2019, 9, 3.	6.2	39
68	Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma. Cancer Journal (Sudbury, Mass), 2019, 25, 19-31.	2.0	7
69	Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia, 2019, 33, 1291-1296.	7.2	36
70	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of reâ€treatment with daratumumab among refractory patients. Cancer, 2019, 125, 2991-3000.	4.1	73
71	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nature Communications, 2019, 10, 1911.	12.8	109
72	Daratumumab in multiple myeloma. Cancer, 2019, 125, 2364-2382.	4.1	100

#	Article	IF	Citations
73	Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e118-e119.	0.4	2
74	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer Journal, 2019, 9, 94.	6.2	104
75	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq1 1 0.784314 rgBT /Over	7.4	3
76	Safety and survival outcomes for bloodless transplantation in patients with myeloma. Cancer, 2019, 125, 185-193.	4.1	4
77	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer, 2019, 125, 416-423.	4.1	36
78	Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy. JCI Insight, 2019, 4, .	5.0	107
79	Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. Blood, 2019, 134, 1872-1872.	1.4	3
80	Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor. Blood, 2019, 134, 3192-3192.	1.4	22
81	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. Blood, 2019, 134, 3140-3140.	1.4	13
82	The Role of Proteasome Activator PA28Î± in Multiple Myeloma. Blood, 2019, 134, 5499-5499.	1.4	0
83	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq1 1 0.784314 rgBT /Over	7.4	3
84	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2018, 36, 859-866.	1.6	140
85	Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. Journal of Oncology Practice, 2018, 14, 414-422.	2.5	35
86	32 Laboratory Evaluation for Therapy-Related Myeloid Neoplasia-Associated Changes After Autotransplant for Multiple Myeloma. American Journal of Clinical Pathology, 2018, 149, S180-S180.	0.7	0
87	Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. Journal of Oncology Practice, 2018, 14, 561-564.	2.5	8
88	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer, 2018, 124, 4342-4349.	4.1	29
89	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature Communications, 2018, 9, 5341.	12.8	356
90	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica, 2018, 103, 2079-2087.	3.5	225

#	Article	IF	Citations
91	Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT). Biology of Blood and Marrow Transplantation, 2018, 24, S137-S138.	2.0	0
92	Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. Cancer, 2018, 124, 4358-4365.	4.1	4
93	How Does Genetics and MRD Impact Treatment or Doesnâ€™t It?. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S69-S72.	0.4	0
94	Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S250-S251.	0.4	0
95	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S249-S250.	0.4	6
96	Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. Future Oncology, 2018, 14, 3111-3121.	2.4	10
97	Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma. JAMA Oncology, 2018, 4, e183267.	7.1	63
98	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. Blood, 2018, 132, 3241-3241.	1.4	1
99	Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor. Blood, 2018, 132, 3270-3270.	1.4	6
100	Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies. Blood, 2018, 132, 3288-3288.	1.4	10
101	Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses. Blood, 2018, 132, 2655-2655.	1.4	2
102	Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma. Blood, 2018, 132, 952-952.	1.4	6
103	Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy. Blood, 2018, 132, 1884-1884.	1.4	1
104	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. Blood, 2018, 132, 598-598.	1.4	17
105	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. Blood, 2018, 132, 2157-2157.	1.4	1
106	Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. Blood, 2018, 132, 3282-3282.	1.4	11
107	Safety and Efficacy of Evomelaâ„¢ in Myeloma Autotransplants. Blood, 2018, 132, 3446-3446.	1.4	2
108	Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. Blood, 2018, 132, 3294-3294.	1.4	2

#	Article	IF	Citations
109	Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 5647-5647.	1.4	3
110	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. Blood, 2018, 132, 3302-3302.	1.4	0
111	The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study. Blood, 2018, 132, 5911-5911.	1.4	1
112	Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy. Blood, 2018, 132, 405-405.	1.4	3
113	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq1 1 0.784314 rgBT /Over	1.4	
114	Bone marrow microenvironmentâ€“derived signals induce Mcl-1 dependence in multiple myeloma. Blood, 2017, 129, 1969-1979.	1.4	85
115	Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood, 2017, 129, 3033-3037.	1.4	71
116	Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study. Infection Control and Hospital Epidemiology, 2017, 38, 651-657.	1.8	10
117	The Role of Consolidation and Maintenance in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S143.	0.4	0
118	Development of GLUT4-selective antagonists for multiple myeloma therapy. European Journal of Medicinal Chemistry, 2017, 139, 573-586.	5.5	31
119	Safety and Engraftment Parameters for Bloodless Transplants among Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e68-e69.	0.4	0
120	Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM Based on Prior Lines and Treatment Exposure: CASTOR. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e133.	0.4	0
121	RVD is a Superior Induction Regimen Compared to VCD Among Transplant-Eligible Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e137-e138.	0.4	3
122	High-risk Multiple Myeloma: Definition and Management. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S80-S87.	0.4	34
123	TG02 inhibits proteasome inhibitorâ€“induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma. Blood Advances, 2017, 1, 1848-1853.	5.2	1
124	CD86 regulates myeloma cell survival. Blood Advances, 2017, 1, 2307-2319.	5.2	15
125	An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2017, 35, 8002-8002.	1.6	15
126	Safety and efficacy of daratumumab-based regimens in elderly (â‰¥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.. Journal of Clinical Oncology, 2017, 35, 8033-8033.	1.6	3

#	Article	IF	Citations
127	Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital. Journal of Stem Cell Research & Therapy, 2016, 06, .	0.3	3
128	New Targets and New Agents in High-Risk Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e431-e441.	3.8	12
129	Death by a thousand cuts: the slow demise of chemotherapy. Cancer, 2016, 122, 1971-1973.	4.1	1
130	Central nervous system involvement by multiple myeloma: A multiâ€institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 2016, 91, 575-580.	4.1	83
131	Myeloma Is Not a Single Disease. Journal of Oncology Practice, 2016, 12, 287-292.	2.5	10
132	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1609-1618.	2.5	18
133	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 375, 754-766.	27.0	1,246
134	Is Maintenance Therapy for Everyone?. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S139-S144.	0.4	4
135	Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation. Cancer, 2016, 122, 3207-3214.	4.1	16
136	Meningeal Myelomatosis. Journal of Oncology Practice, 2016, 12, 187-188.	2.5	0
137	Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. Cancer Biology and Therapy, 2016, 17, 769-777.	3.4	17
138	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leukemia and Lymphoma, 2016, 57, 2071-2076.	1.3	30
139	Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor. Blood, 2016, 128, 1150-1150.	1.4	30
140	B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma. Blood, 2016, 128, 2108-2108.	1.4	2
141	Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood, 2016, 128, 2124-2124.	1.4	2
142	Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2016, 128, 2142-2142.	1.4	34
143	HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS). Blood, 2016, 128, 3250-3250.	1.4	1
144	Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). Blood, 2016, 128, 3307-3307.	1.4	16

#	Article	IF	Citations
145	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. Blood, 2016, 128, 491-491.	1.4	21
146	Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients. Blood, 2016, 128, 492-492.	1.4	21
147	New Targets and New Agents in High-Risk Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e431-e441.	3.8	9
148	Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. Oncotarget, 2016, 7, 59727-59741.	1.8	33
149	BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget, 2016, 7, 27753-27763.	1.8	19
150	Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant. Blood, 2016, 128, 4524-4524.	1.4	0
151	Novel combination approaches for myeloma. Hematology American Society of Hematology Education Program, 2015, 2015, 286-293.	2.5	4
152	Treatment options for relapsed and refractory multiple myeloma. Blood, 2015, 125, 3085-3099.	1.4	136
153	Description of the types and content of phase 1 clinical trial consent conversations in practice. Clinical Trials, 2015, 12, 567-574.	1.6	13
154	Plerixafor in combination with granulocyteâ€“colonyâ€stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Transfusion, 2015, 55, 2351-2357.	1.6	6
155	Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients. Cancer, 2015, 121, 853-862.	4.1	1
156	In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy. Journal of Biological Chemistry, 2015, 290, 14441-14453.	3.4	52
157	Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leukemia and Lymphoma, 2015, 56, 383-389.	1.3	7
158	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). Blood, 2015, 126, 3036-3036.	1.4	12
159	Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood, 2015, 126, 4241-4241.	1.4	6
160	Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood, 2015, 126, 4246-4246.	1.4	2
161	Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs). Blood, 2015, 126, 5344-5344.	1.4	2
162	Solitary Plasmacytoma Incidence, Mortality, and Survival Trends in the United States. Blood, 2015, 126, 5629-5629.	1.4	0

#	Article	IF	Citations
163	Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT). Blood, 2015, 126, 4202-4202.	1.4	0
164	Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States. Blood, 2015, 126, 4508-4508.	1.4	1
165	The Role of County-Level Contextual Predictors in Multiple Myeloma Mortality. Blood, 2015, 126, 3325-3325.	1.4	0
166	Optimal Dosing of Melphalan As High-Dose Therapy Before Autologous Hematopoietic Stem Cell Transplantation in Myeloma Patients With Solitary Kidney: A Case Series. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e59-e63.	0.4	3
167	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncology, The, 2014, 15, 333-342.	10.7	256
168	Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 852-857.	2.0	29
169	Simplified Technique for Administration of High Dose Melphalan. Biology of Blood and Marrow Transplantation, 2014, 20, S291-S292.	2.0	0
170	Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma. Blood, 2014, 124, 2139-2139.	1.4	13
171	Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial. Blood, 2014, 124, 32-32.	1.4	14
172	Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood, 2014, 124, 4737-4737.	1.4	3
173	Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. Blood, 2014, 124, 5773-5773.	1.4	1
174	Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea. Blood, 2014, 124, 5779-5779.	1.4	4
175	Incidence and Geographic Distribution of Adult Acute Leukemia in the State of Georgia. Southern Medical Journal, 2014, 107, 497-500.	0.7	3
176	Outcomes for Myeloma in the Era of Lenalidomide Maintenance Are Not Different Among Ethnic Groups Following Autologous Transplant. Blood, 2014, 124, 3973-3973.	1.4	0
177	Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma. Blood, 2014, 124, 3447-3447.	1.4	0
178	Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies. Blood, 2014, 124, 2525-2525.	1.4	0
179	Risk Factors for Development of Myeloma: Role of Smoking and Alcohol. Blood, 2014, 124, 2604-2604.	1.4	0
180	Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells. Blood, 2014, 124, 4726-4726.	1.4	0

#	Article	IF	Citations
181	Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells. Biology of Blood and Marrow Transplantation, 2013, 19, S191.	2.0	0
182	Bortezomibâ€containing induction regimens in transplantâ€eligible myeloma patients. Cancer, 2013, 119, 4119-4128.	4.1	36
183	Temporal Changes in Plerixafor Administration and Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 1393-1395.	2.0	18
184	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica, 2013, 98, 1753-1761.	3.5	300
185	From Single Nucleotide Polymorphisms to Constant Immunosuppression: Mesenchymal Stem Cell Therapy for Autoimmune Diseases. BioMed Research International, 2013, 2013, 1-8.	1.9	9
186	Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Annals of Oncology, 2013, 24, 441-448.	1.2	79
187	Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. Biologics: Targets and Therapy, 2013, 7, 13.	3.2	13
188	Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma. Blood, 2013, 122, 1924-1924.	1.4	2
189	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). Blood, 2013, 122, 1969-1969.	1.4	12
190	Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low Î±-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study. Blood, 2013, 122, 285-285.	1.4	14
191	Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data. Blood, 2013, 122, 3135-3135.	1.4	8
192	Efficacy Of ABT-199 In Multiple Myeloma. Blood, 2013, 122, 4453-4453.	1.4	2
193	Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).. Journal of Clinical Oncology, 2013, 31, 8540-8540.	1.6	1
194	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2013, 31, 8584-8584.	1.6	3
195	Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit.. Journal of Clinical Oncology, 2013, 31, 7035-7035.	1.6	0
196	Access To Therapeutic Surgical Procedures For Pathologic Fractures In Multiple Myeloma Patients: Analysis of Nationwide Inpatient Sample (NIS). Blood, 2013, 122, 1709-1709.	1.4	0
197	Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT). Blood, 2013, 122, 5606-5606.	1.4	0
198	Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample. Blood, 2013, 122, 5582-5582.	1.4	0

#	Article	IF	Citations
199	P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma. Blood, 2013, 122, 1929-1929.	1.4	0
200	Correlation Among Different Plasma Cell Disorders Markers and Immunoglobulin Heavy Light Chains (HLC). Blood, 2013, 122, 3148-3148.	1.4	0
201	Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma. Blood, 2013, 122, 3171-3171.	1.4	0
202	Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma. Blood, 2013, 122, 1856-1856.	1.4	0
203	Sequential or combination therapy for multiple myeloma. Expert Review of Hematology, 2012, 5, 533-545.	2.2	5
204	Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease. Current Drug Delivery, 2012, 9, 41-51.	1.6	4
205	Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry. Blood, 2012, 120, 2072-2072.	1.4	3
206	Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study. Blood, 2012, 120, 336-336.	1.4	7
207	Impact of Body Mass Index (BMI) On Overall Survival in Myeloma. Blood, 2012, 120, 4289-4289.	1.4	1
208	Management of Back Pain in Myeloma Patients Using Vertebral Augmentation: A Practical Approach to Elimination of Pain and Improvement of Functional Status. Blood, 2012, 120, 4713-4713.	1.4	0
209	Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins. Blood, 2012, 120, 4024-4024.	1.4	0
210	Consolidation with High Dose Therapy and Autologous Stem Cell Transplant Improves Survival for Patients with Mantle Cell Lymphoma. Blood, 2012, 120, 2006-2006.	1.4	0
211	Racial differences in the presentation and outcomes of diffuse large Bâ€cell lymphoma in the United States. Cancer, 2011, 117, 2530-2540.	4.1	125
212	Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis. Blood, 2011, 118, 1855-1855.	1.4	4
213	The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),. Blood, 2011, 118, 3994-3994.	1.4	5
214	Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL). Blood, 2011, 118, 775-775.	1.4	7
215	A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials,. Blood, 2011, 118, 3954-3954.	1.4	0
216	Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis. Blood, 2011, 118, 1959-1959.	1.4	0

#	Article	IF	Citations
217	Improving Induction Therapy in Multiple Myeloma. Current Hematologic Malignancy Reports, 2010, 5, 119-128.	2.3	4
218	Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma. Cancer, 2010, 116, 3143-3151.	4.1	32
219	A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study. Clinical Cancer Research, 2010, 16, 5079-5086.	7.0	94
220	Supportive Therapies in Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 971-979.	4.9	4
221	The Importance of Complete Response in Outcomes in Myeloma. Cancer Journal (Sudbury, Mass), 2009, 15, 465-472.	2.0	9
222	Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience.. Blood, 2009, 114, 3888-3888.	1.4	1
223	Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates. Journal of Bone and Mineral Research, 2008, 23, 826-836.	2.8	527
224	Bilateral adrenal hemorrhage: An overlooked cause of hypotension. Journal of Emergency Medicine, 2007, 32, 167-169.	0.7	21
225	Osteonecrosis of the Jaw or Maxilla after Intravenous Bisphosphonates for Multiple Myeloma and Breast Cancer: Long-Term Follow-Up Shows a Slow Rate of Healing.. Blood, 2006, 108, 5121-5121.	1.4	1
226	Thalidomide in the treatment of patients with hepatocellular carcinoma. Cancer, 2005, 103, 749-755.	4.1	107